KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug

All NewsJanuary 9, 2026

KalVista reports early EKTERLY sales momentum, rising prescriber adoption and global regulatory approvals following the drug’s 2025 launch.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent